Document Detail

Vesicular pityriasis rosea: response to erythromycin treatment.
MedLine Citation:
PMID:  15324412     Owner:  NLM     Status:  MEDLINE    
Pityriasis rosea (PR) is a relatively common disease although its aetiology has not yet been identified. It occurs worldwide and there is no racial susceptibility factor. It usually affects teenagers and young adults between 10 and 35 years of age. Typical PR is much easier to diagnose than the rare atypical forms. We report a rare case of vesicular PR in a black woman who had vesicular lesions limited to her palms and soles in addition to regular typical lesions. We devised an efficient oral erythromycin treatment for this patient.
S B Miranda; O Lupi; E Lucas
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of the European Academy of Dermatology and Venereology : JEADV     Volume:  18     ISSN:  0926-9959     ISO Abbreviation:  J Eur Acad Dermatol Venereol     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-08-24     Completed Date:  2005-01-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9216037     Medline TA:  J Eur Acad Dermatol Venereol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  622-5     Citation Subset:  IM    
Copyright Information:
Copyright 2004 European Academy of Dermatology and Venereology
Dermatology Department, Clinical Hospital of Federal University/UFES, Vitória, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Anti-Bacterial Agents / administration & dosage
Diagnosis, Differential
Erythromycin / administration & dosage
Pityriasis Rosea / diagnosis*,  pathology
Reg. No./Substance:
0/Anti-Bacterial Agents; 114-07-8/Erythromycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A case of porokeratotic eccrine ostial and dermal duct naevus of late onset.
Next Document:  Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream.